

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Crowley John F</u>  (Last) (First) (Middle) <u>C/O AMICUS THERAPEUTICS, INC.</u> <u>1 CEDAR BROOK DRIVE</u>  (Street) <u>CRANBURY NJ 08512</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS INC [ FOLD ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>Chairman &amp; CEO</b>
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/12/2017</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year) <u>10/17/2017</u>	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/12/2017		M <sup>(1)</sup>		380,000	A	\$14.2495 <sup>(2)</sup>	708,001	D	
Common Stock	10/12/2017		S <sup>(1)</sup>		380,000	D	\$14.2495 <sup>(3)</sup>	328,001	D	
Common Stock	10/13/2017		M <sup>(1)</sup>		22,160	A	\$14.7503 <sup>(4)</sup>	350,161	D	
Common Stock	10/13/2017		S <sup>(1)</sup>		22,160	D	\$14.7503 <sup>(5)</sup>	328,001	D	
Common Stock	10/16/2017		M <sup>(1)</sup>		47,135	A	\$14.75	375,136	D	
Common Stock	10/16/2017		S <sup>(1)</sup>		47,135	D	\$14.75	328,001	D	
Common Stock								64,895	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$6.45	10/12/2017		M <sup>(1)</sup>			5,783	02/15/2016	02/15/2022	Common Stock	5,783	\$0.00	131,024	D	
Stock Options (right to buy)	\$4.38	10/12/2017		M <sup>(1)</sup>			13,622	06/04/2016	06/04/2022	Common Stock	13,622	\$0.00	136,378	D	
Stock Options (right to buy)	\$3.53	10/12/2017		M <sup>(1)</sup>			3,462	01/28/2017	01/28/2023	Common Stock	3,462	\$0.00	161,538	D	
Stock Options (right to buy)	\$2.52	10/12/2017		M <sup>(1)</sup>			165,000	06/18/2017	06/18/2023	Common Stock	165,000	\$0.00	0	D	
Stock Options (right to buy)	\$3.19	10/12/2017		M <sup>(1)</sup>			192,133	01/03/2015	01/03/2024	Common Stock	192,133	\$0.00	20,972	D	
Stock Options (right to buy)	\$3.53	10/13/2017		M <sup>(1)</sup>			22,160	01/28/2017	01/28/2023	Common Stock	22,160	\$0.00	139,378	D	
Stock Options (right to buy)	\$3.53	10/16/2017		M <sup>(1)</sup>			47,135	01/28/2017	01/28/2023	Common Stock	47,135	\$0.00	92,243	D	

**Explanation of Responses:**

- The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.09 to \$14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

3. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.09 to \$14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.75 to \$14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

5. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.75 to \$14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

**Remarks:**

This Form 4 amendment corrects the reporting person's Remarks from the originally filed Form 4. The Remarks should read as follows: Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. The total shares sold represented less than 14% of Mr. Crowley's holdings of securities of the company and after these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares.

/s/ John F. Crowley

10/20/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**